Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (yeni pencere açar)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Kaynak‎: Cancer 2013;119(21):3784-7.

İndeks‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (yeni pencere açar)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (yeni pencere açar)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Kaynak‎: Lancet 1989;334(8655):122-4.

İndeks‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (yeni pencere açar)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (yeni pencere açar)

Ben-Bassat I, Douer D, Ramot B.

Kaynak‎: Eur J Haematol 1990;45(2):86-9.

İndeks‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (yeni pencere açar)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (yeni pencere açar)

Dean A, Tuffin P.

Kaynak‎: J Pain Symptom Manage 1997;13(1):20-4.

İndeks‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (yeni pencere açar)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (yeni pencere açar)

Ford PA, Grant SJ, Mick R, Keck G.

Kaynak‎: J Clin Oncol 2015;33(15):1674-9.

İndeks‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (yeni pencere açar)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (yeni pencere açar)

Garewal HS, Durie BG.

Kaynak‎: Scand J Haematol 1985;35(5):497-500.

İndeks‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (yeni pencere açar)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (yeni pencere açar)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Kaynak‎: Cancer 2006;107(1):136-40.

İndeks‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (yeni pencere açar)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (yeni pencere açar)

Marshall A, Li A, Drucker A, Dzik W.

Kaynak‎: Hematol Oncol 2016;34(3):147-53.

İndeks‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (yeni pencere açar)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (yeni pencere açar)

Prokopchuk-Gauk O, Brose K.

Kaynak‎: Cureus 2015;7(12):e428.

İndeks‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (yeni pencere açar)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (yeni pencere açar)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Kaynak‎: Leuk Lymphoma 1995;19(1-2):141-4.

İndeks‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (yeni pencere açar)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (yeni pencere açar)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Kaynak‎: Hematol Oncol 2008;26(4):241-6.

İndeks‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (yeni pencere açar)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (yeni pencere açar)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Kaynak‎: Am J Hematol 2006;81(9):720.

İndeks‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (yeni pencere açar)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (yeni pencere açar)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Kaynak‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

İndeks‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (yeni pencere açar)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (yeni pencere açar)

Erduran E, Bahadir A, Mutlu M.

Kaynak‎: Eur J Clin Med Oncol 2011;3(5):1-4.

İndeks‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (yeni pencere açar)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (yeni pencere açar)

Franchini M, Veneri D, Lippi G.

Kaynak‎: Bone Marrow Transplant 2007;39(12):729-35.

İndeks‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (yeni pencere açar)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (yeni pencere açar)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Kaynak‎: Am J Hematol 2002;69(3):219-22.

İndeks‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (yeni pencere açar)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (yeni pencere açar)

Hsieh A, Cheong I.

Kaynak‎: Am J Emerg Med 2007;25(9):1085.e1-2.

İndeks‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (yeni pencere açar)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (yeni pencere açar)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Kaynak‎: Haemostasis 1996;26 Suppl 1:159-64.

İndeks‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (yeni pencere açar)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (yeni pencere açar)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Kaynak‎: Med Oncol 2010;27(1):16-9.

İndeks‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (yeni pencere açar)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (yeni pencere açar)

Vidarsson B, Önundarson PT.

Kaynak‎: Thromb Haemost 2000;83(4):634-5.

İndeks‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (yeni pencere açar)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (yeni pencere açar)

Zver S, Andoljšek D, Černelč P.

Kaynak‎: Eur J Haematol 2004;72(6):455-6.

İndeks‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (yeni pencere açar)

Management of bleeding complications of hematologic malignancies. (yeni pencere açar)

Green D.

Kaynak‎: Semin Thromb Hemost 2007;33(4):427-34.

İndeks‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (yeni pencere açar)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (yeni pencere açar)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Kaynak‎: Int J Lab Hematol 2013;35(4):457-9.

İndeks‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (yeni pencere açar)

Management of bleeding in patients with advanced cancer. (yeni pencere açar)

Pereira J, Phan T.

Kaynak‎: Oncologist 2004;9(5):561-70.

İndeks‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (yeni pencere açar)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (yeni pencere açar)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Kaynak‎: Haematologica 1997;82(5):584-7.

İndeks‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (yeni pencere açar)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (yeni pencere açar)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Kaynak‎: Bull Cancer 2006;93(2):E7-12.

İndeks‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (yeni pencere açar)